Skip to main content
Cerveau's IND for tau PET tracer wins FDA approval

The FDA has approved the investigational new drug application filed by Cerveau Technologies for its MK-6240, a tau PET imaging agent licensed from Merck. Cerveau will work with pharmaceutical partners to assess the tracer in imaging neurofibrillary tangles in the brain.

Full Story: